A citation-based method for searching scientific literature

Jean-Pascal H Machiels, Stéphanie Henry, Sylvie Zanetta, Marie-Christine Kaminsky, Nicolas Michoux, Denis Rommel, Sandra Schmitz, Emmanuelle Bompas, Anne-Françoise Dillies, Sandrine Faivre, Anne Moxhon, Thierry Duprez, Joel Guigay. J Clin Oncol 2010
Times Cited: 118







List of co-cited articles
969 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Phase II evaluation of sorafenib in advanced and metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group Study S0420.
Stephen K Williamson, James Moon, Chao H Huang, Perry P Guaglianone, Michael LeBlanc, Gregory T Wolf, Susan G Urba. J Clin Oncol 2010
83
51

Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Jan B Vermorken, Ricard Mesia, Fernando Rivera, Eva Remenar, Andrzej Kawecki, Sylvie Rottey, Jozsef Erfan, Dmytro Zabolotnyy, Heinz-Roland Kienzer, Didier Cupissol,[...]. N Engl J Med 2008
40

Phase II study of sunitinib malate in head and neck squamous cell carcinoma.
Nicholas W Choong, Mark Kozloff, David Taber, H Shawn Hu, James Wade, Percy Ivy, Theodore G Karrison, Allison Dekker, Everett E Vokes, Ezra E W Cohen. Invest New Drugs 2010
52
73

Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study.
Ezra E W Cohen, Darren W Davis, Theodore G Karrison, Tanguy Y Seiwert, Stuart J Wong, Sreenivasa Nattam, Mark F Kozloff, Joseph I Clark, Duen-Hwa Yan, Wen Liu,[...]. Lancet Oncol 2009
195
36

Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma.
Christine Elser, Lillian L Siu, Eric Winquist, Mark Agulnik, Gregory R Pond, Soo F Chin, Peggy Francis, Robin Cheiken, James Elting, Angela McNabola,[...]. J Clin Oncol 2007
163
34

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.
James A Bonner, Paul M Harari, Jordi Giralt, Nozar Azarnia, Dong M Shin, Roger B Cohen, Christopher U Jones, Ranjan Sur, David Raben, Jacek Jassem,[...]. N Engl J Med 2006
32

Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected].
J Simon W Stewart, Ezra E W Cohen, Lisa Licitra, Carla M L Van Herpen, Chonlakiet Khorprasert, Denis Soulieres, Pavel Vodvarka, Danny Rischin, Avgust M Garin, Fred R Hirsch,[...]. J Clin Oncol 2009
236
28

A phase II study of sunitinib in patients with recurrent and/or metastatic non-nasopharyngeal head and neck cancer.
George Fountzilas, Anna Fragkoulidi, Anna Kalogera-Fountzila, Martha Nikolaidou, Mattheos Bobos, Julien Calderaro, Felipe Andreiuolo, Marios Marselos. Cancer Chemother Pharmacol 2010
41
65

Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy.
Jan B Vermorken, José Trigo, Ricardo Hitt, Piotr Koralewski, Eduardo Diaz-Rubio, Frédéric Rolland, Rainald Knecht, Nadia Amellal, Armin Schueler, José Baselga. J Clin Oncol 2007
658
25


Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial.
Jean-Pascal Machiels, Somasundaram Subramanian, Agnes Ruzsa, Gabor Repassy, Igor Lifirenko, Annika Flygare, Per Sørensen, Tina Nielsen, Steen Lisby, Paul M J Clement. Lancet Oncol 2011
154
21

Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck.
A Argiris, A P Kotsakis, T Hoang, F P Worden, P Savvides, M K Gibson, R Gyanchandani, G R Blumenschein, H X Chen, J R Grandis,[...]. Ann Oncol 2013
94
22

Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival.
James A Bonner, Paul M Harari, Jordi Giralt, Roger B Cohen, Christopher U Jones, Ranjan K Sur, David Raben, Jose Baselga, Sharon A Spencer, Junming Zhu,[...]. Lancet Oncol 2010
20

Phase II trial of pemetrexed and bevacizumab in patients with recurrent or metastatic head and neck cancer.
Athanassios Argiris, Michalis V Karamouzis, William E Gooding, Barton F Branstetter, Shilong Zhong, Luis E Raez, Panayiotis Savvides, Marjorie Romkes. J Clin Oncol 2011
69
28


The mutational landscape of head and neck squamous cell carcinoma.
Nicolas Stransky, Ann Marie Egloff, Aaron D Tward, Aleksandar D Kostic, Kristian Cibulskis, Andrey Sivachenko, Gregory V Kryukov, Michael S Lawrence, Carrie Sougnez, Aaron McKenna,[...]. Science 2011
18


Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1.
Nishant Agrawal, Mitchell J Frederick, Curtis R Pickering, Chetan Bettegowda, Kyle Chang, Ryan J Li, Carole Fakhry, Tong-Xin Xie, Jiexin Zhang, Jing Wang,[...]. Science 2011
17

Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma.
Heather D Brooks, Bonnie S Glisson, B Nebiyou Bekele, Faye M Johnson, Lawrence E Ginsberg, Adel El-Naggar, Kirk S Culotta, Naoko Takebe, John Wright, Hai T Tran,[...]. Cancer 2011
73
19

Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck.
José Baselga, José M Trigo, Jean Bourhis, Jacques Tortochaux, Hernán Cortés-Funes, Ricardo Hitt, Pere Gascón, Nadia Amellal, Andreas Harstrick, André Eckardt. J Clin Oncol 2005
357
13

Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck.
Roy S Herbst, Matthew Arquette, Dong M Shin, Karel Dicke, Everett E Vokes, Nozar Azarnia, Waun Ki Hong, Merrill S Kies. J Clin Oncol 2005
286
13

Human papillomavirus and survival of patients with oropharyngeal cancer.
K Kian Ang, Jonathan Harris, Richard Wheeler, Randal Weber, David I Rosenthal, Phuc Felix Nguyen-Tân, William H Westra, Christine H Chung, Richard C Jordan, Charles Lu,[...]. N Engl J Med 2010
13


Effects of lapatinib monotherapy: results of a randomised phase II study in therapy-naive patients with locally advanced squamous cell carcinoma of the head and neck.
J M Del Campo, R Hitt, P Sebastian, C Carracedo, D Lokanatha, J Bourhis, S Temam, D Cupissol, D De Raucourt, N Maroudias,[...]. Br J Cancer 2011
78
15

A phase II study of lapatinib in recurrent/metastatic squamous cell carcinoma of the head and neck.
Jonas A de Souza, Darren W Davis, Yujian Zhang, Arun Khattri, Tanguy Y Seiwert, Serdal Aktolga, Stuart J Wong, Mark F Kozloff, Sreenivasa Nattam, Mark W Lingen,[...]. Clin Cancer Res 2012
74
16

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.
Robert L Ferris, George Blumenschein, Jerome Fayette, Joel Guigay, A Dimitrios Colevas, Lisa Licitra, Kevin Harrington, Stefan Kasper, Everett E Vokes, Caroline Even,[...]. N Engl J Med 2016
12

Hemorrhagic complications in a phase II study of sunitinib in patients of nasopharyngeal carcinoma who has previously received high-dose radiation.
E P Hui, B B Y Ma, A D King, F Mo, S L Chan, M K M Kam, H H Loong, A T Ahuja, B C Y Zee, A T C Chan. Ann Oncol 2011
70
15

Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer.
Tanguy Y Seiwert, Daniel J Haraf, Ezra E W Cohen, Kerstin Stenson, Mary Ellyn Witt, Allison Dekker, Masha Kocherginsky, Ralph R Weichselbaum, Helen X Chen, Everett E Vokes. J Clin Oncol 2008
108
11

Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting.
John C Sok, Francesca M Coppelli, Sufi M Thomas, Miriam N Lango, Sichuan Xi, Jennifer L Hunt, Maria L Freilino, Michael W Graner, Carol J Wikstrand, Darell D Bigner,[...]. Clin Cancer Res 2006
352
11

Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma.
K Kian Ang, Brian A Berkey, Xiaoyu Tu, Hua-Zhong Zhang, Ruth Katz, Elizabeth H Hammond, Karen K Fu, Luka Milas. Cancer Res 2002
876
11


A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck.
A R Abdul Razak, D Soulières, S A Laurie, S J Hotte, S Singh, E Winquist, S Chia, C Le Tourneau, P-F Nguyen-Tan, E X Chen,[...]. Ann Oncol 2013
69
15

Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial.
Jean-Pascal H Machiels, Robert I Haddad, Jérôme Fayette, Lisa F Licitra, Makoto Tahara, Jan B Vermorken, Paul M Clement, Thomas Gauler, Didier Cupissol, Juan José Grau,[...]. Lancet Oncol 2015
241
11

Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival.
J Rubin Grandis, M F Melhem, W E Gooding, R Day, V A Holst, M M Wagener, S D Drenning, D J Tweardy. J Natl Cancer Inst 1998
850
10

Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas.
Christine H Chung, Kim Ely, Loris McGavran, Marileila Varella-Garcia, Joel Parker, Natalie Parker, Carolyn Jarrett, Jesse Carter, Barbara A Murphy, James Netterville,[...]. J Clin Oncol 2006
417
10

Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Jan B Vermorken, Eva Remenar, Carla van Herpen, Thierry Gorlia, Ricard Mesia, Marian Degardin, John S Stewart, Svetislav Jelic, Jan Betka, Joachim H Preiss,[...]. N Engl J Med 2007
10

Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck.
Ezra E W Cohen, Fred Rosen, Walter M Stadler, Wendy Recant, Kerstin Stenson, Dezheng Huo, Everett E Vokes. J Clin Oncol 2003
466
10

Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial.
Carole Fakhry, William H Westra, Sigui Li, Anthony Cmelak, John A Ridge, Harlan Pinto, Arlene Forastiere, Maura L Gillison. J Natl Cancer Inst 2008
10

Combination of sunitinib, cetuximab and irradiation in an orthotopic head and neck cancer model.
A Bozec, A Sudaka, N Toussan, J-L Fischel, M-C Etienne-Grimaldi, G Milano. Ann Oncol 2009
36
27


Phase II study of figitumumab in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: clinical activity and molecular response (GORTEC 2008-02).
S Schmitz, M-C Kaminsky-Forrett, S Henry, S Zanetta, L Geoffrois, E Bompas, A Moxhon, L Mignion, J Guigay, L Knoops,[...]. Ann Oncol 2012
58
17

Vandetanib restores head and neck squamous cell carcinoma cells' sensitivity to cisplatin and radiation in vivo and in vitro.
Daisuke Sano, Fumihiko Matsumoto, David R Valdecanas, Mei Zhao, David P Molkentine, Yoko Takahashi, Ehab Y Hanna, Vali Papadimitrakopoulou, John Heymach, Luka Milas,[...]. Clin Cancer Res 2011
57
17


The mTOR-targeting drug temsirolimus enhances the growth-inhibiting effects of the cetuximab-bevacizumab-irradiation combination on head and neck cancer xenografts.
Alexandre Bozec, Marie-Christine Etienne-Grimaldi, Jean-Louis Fischel, Anne Sudaka, Nicolas Toussan, Patricia Formento, Gérard Milano. Oral Oncol 2011
30
33

Phase II trial of single-agent foretinib (GSK1363089) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
Tanguy Seiwert, John Sarantopoulos, Howard Kallender, Stewart McCallum, Harold N Keer, George Blumenschein. Invest New Drugs 2013
51
19

A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma.
Julie E Bauman, Hugo Arias-Pulido, Sang-Joon Lee, M Houman Fekrazad, Hiroyuki Ozawa, Elana Fertig, Jason Howard, Justin Bishop, Hao Wang, Garth T Olson,[...]. Oral Oncol 2013
65
15

Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an eastern cooperative oncology group trial.
Athanassios Argiris, Musie Ghebremichael, Jill Gilbert, Ju-Whei Lee, Kamakshi Sachidanandam, Jill M Kolesar, Barbara Burtness, Arlene A Forastiere. J Clin Oncol 2013
122
10

Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.
Jan B Vermorken, Jan Stöhlmacher-Williams, Irina Davidenko, Lisa Licitra, Eric Winquist, Cristian Villanueva, Paolo Foa, Sylvie Rottey, Krzysztof Skladowski, Makoto Tahara,[...]. Lancet Oncol 2013
295
10

A phase 2 study of bevacizumab with cisplatin plus intensity-modulated radiation therapy for stage III/IVB head and neck squamous cell cancer.
Matthew G Fury, Nancy Y Lee, Eric Sherman, Donna Lisa, Katherine Kelly, Brynna Lipson, Diane Carlson, Hilda Stambuk, Sofia Haque, Ronglai Shen,[...]. Cancer 2012
47
21

In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.
Dirk B Mendel, A Douglas Laird, Xiaohua Xin, Sharianne G Louie, James G Christensen, Guangmin Li, Randall E Schreck, Tinya J Abrams, Theresa J Ngai, Leslie B Lee,[...]. Clin Cancer Res 2003
9


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.